The evolving role of DNA inter-strand crosslinks in chemotherapy.

[1]  P. Fei,et al.  Fanconi Anemia Signaling and Cancer. , 2017, Trends in cancer.

[2]  P. McHugh,et al.  RPA activates the XPF‐ERCC1 endonuclease to initiate processing of DNA interstrand crosslinks , 2017, The EMBO journal.

[3]  R. Hromas,et al.  Drugging the Cancers Addicted to DNA Repair , 2017, Journal of the National Cancer Institute.

[4]  Nathan E. Price,et al.  A role for the base excision repair enzyme NEIL3 in replication-dependent repair of interstrand DNA cross-links derived from psoralen and abasic sites. , 2017, DNA repair.

[5]  C. R. Leemans,et al.  The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics , 2016, Molecular Cancer Therapeutics.

[6]  J. Walter,et al.  Replication-Dependent Unhooking of DNA Interstrand Cross-Links by the NEIL3 Glycosylase , 2016, Cell.

[7]  P. Bassi,et al.  Mitomycin C: New Strategies to Improve Efficacy of a Well-Known Therapy , 2016, Urologia.

[8]  V. Serretta,et al.  Mitomycin C from Birth to Adulthood , 2016, Urologia.

[9]  E. Swisher,et al.  Biomarkers of Response and Resistance to DNA Repair Targeted Therapies , 2016, Clinical Cancer Research.

[10]  David T. Long,et al.  p97 Promotes a Conserved Mechanism of Helicase Unloading during DNA Cross-Link Repair , 2016, Molecular and Cellular Biology.

[11]  N. Tunariu,et al.  Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies. , 2016 .

[12]  M. Cohn,et al.  Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway , 2016, Cellular and Molecular Life Sciences.

[13]  Weidong Wang,et al.  FANCM interacts with PCNA to promote replication traverse of DNA interstrand crosslinks , 2016, Nucleic acids research.

[14]  J. Walter,et al.  What is the DNA repair defect underlying Fanconi anemia? , 2015, Current opinion in cell biology.

[15]  J. Masson,et al.  DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles’ Heel of Cancer , 2015, Biomolecules.

[16]  M. Ibrahim,et al.  Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp , 2015, Cancer Cell International.

[17]  P. Jallepalli,et al.  ATR-mediated phosphorylation of FANCI regulates dormant origin firing in response to replication stress. , 2015, Molecular cell.

[18]  Martin Kircher,et al.  Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. , 2015, Cancer discovery.

[19]  James M. Dewar,et al.  DNA interstrand cross-link repair requires replication fork convergence , 2014, Nature Structural &Molecular Biology.

[20]  J. Walter,et al.  BRCA1 promotes unloading of the CMG helicase from a stalled DNA replication fork. , 2014, Molecular cell.

[21]  P. Knipscheer,et al.  XPF-ERCC1 acts in Unhooking DNA interstrand crosslinks in cooperation with FANCD2 and FANCP/SLX4. , 2014, Molecular cell.

[22]  G. Kibria,et al.  Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system , 2013, Archives of Pharmacal Research.

[23]  Weidong Wang,et al.  The DNA translocase FANCM/MHF promotes replication traverse of DNA interstrand crosslinks. , 2013, Molecular cell.

[24]  A. D’Andrea.  BRCA1: a missing link in the Fanconi anemia/BRCA pathway. , 2013, Cancer discovery.

[25]  Jing Huang,et al.  NEIL1 Responds and Binds to Psoralen-induced DNA Interstrand Crosslinks* , 2013, The Journal of Biological Chemistry.

[26]  Molly C. Kottemann,et al.  Fanconi anaemia and the repair of Watson and Crick DNA crosslinks , 2013, Nature.

[27]  Nicola J. Curtin,et al.  DNA repair dysregulation from cancer driver to therapeutic target , 2012, Nature Reviews Cancer.

[28]  J. Jiricny,et al.  Repair of cisplatin-induced DNA interstrand crosslinks by a replication-independent pathway involving transcription-coupled repair and translesion synthesis , 2012, Nucleic acids research.

[29]  Michael M Gottesman,et al.  Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes , 2012, Pharmacological Reviews.

[30]  J. Hartley,et al.  Mechanism of cell death resulting from DNA interstrand cross-linking in mammalian cells , 2011, Cell Death and Disease.

[31]  Rochelle L. Garcia,et al.  Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Walter,et al.  Mechanism of RAD51-Dependent DNA Interstrand Cross-Link Repair , 2011, Science.

[33]  Stephen C. West,et al.  DNA interstrand crosslink repair and cancer , 2011, Nature Reviews Cancer.

[34]  P. Muniandy,et al.  DNA interstrand crosslink repair in mammalian cells: step by step , 2010, Critical reviews in biochemistry and molecular biology.

[35]  S. Elledge,et al.  The Fanconi Anemia Pathway Promotes Replication-Dependent DNA Interstrand Cross-Link Repair , 2009, Science.

[36]  P. Muniandy,et al.  Repair of Laser-localized DNA Interstrand Cross-links in G1 Phase Mammalian Cells* , 2009, The Journal of Biological Chemistry.

[37]  The Human Oxidative DNA Glycosylase NEIL1 Excises Psoralen-induced Interstrand DNA Cross-links in a Three-stranded DNA Structure*S⃞ , 2009, Journal of Biological Chemistry.

[38]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[39]  L. Marzilli,et al.  DNA damage-processing pathways involved in the eukaryotic cellular response to anticancer DNA cross-linking drugs. , 2004, Molecular pharmacology.

[40]  R. Isaacs,et al.  A model for initial DNA lesion recognition by NER and MMR based on local conformational flexibility. , 2004, DNA repair.

[41]  R. Kanaar,et al.  Repair of DNA interstrand cross-links. , 2001, Mutation research.

[42]  M. Grompe,et al.  DNA Replication Is Required To Elicit Cellular Responses to Psoralen-Induced DNA Interstrand Cross-Links , 2000, Molecular and Cellular Biology.

[43]  S. Rajski,et al.  DNA Cross-Linking Agents as Antitumor Drugs. , 1998, Chemical reviews.

[44]  A. Warren,et al.  Detection of mitomycin C-DNA adducts in vivo by 32P-postlabeling: time course for formation and removal of adducts and biochemical modulation. , 1998, Cancer research.

[45]  M. Tomasz,et al.  Bending of DNA by the mitomycin C-induced, GpG intrastrand cross-link. , 1996, Chemical research in toxicology.

[46]  J. Hearst,et al.  Solution structures of psoralen monoadducted and cross-linked DNA oligomers by NMR spectroscopy and restrained molecular dynamics. , 1995, Biochemistry.

[47]  V. Brabec,et al.  Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins. , 1995, Biochemistry.

[48]  M. Tomasz,et al.  Mitomycin C: small, fast and deadly (but very selective). , 1995, Chemistry & biology.

[49]  J. Verweij,et al.  Mitomycin C. , 1990, Cancer chemotherapy and biological response modifiers.

[50]  D. Crothers,et al.  Phased psoralen cross-links do not bend the DNA double helix. , 1988, Biochemistry.

[51]  K. Nakanishi,et al.  Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. , 1987, Science.

[52]  C. Rawlings,et al.  Quantitative aspects of the formation and loss of DNA interstrand crosslinks in Chinese hamster cells following treatment with cis-diamminedichloroplatinum(II) (cisplatin). II. Comparison of results from alkaline elution, DNA renaturation and DNA sedimentation studies. , 1981, Biochimica et biophysica acta.

[53]  J. Hearst,et al.  Synthesis and characterization of new psoralen derivatives with superior photoreactivity with DNA and RNA. , 1977, Biochemistry.

[54]  M. Duvic,et al.  Juvenile mycosis fungoides with large‐cell transformation: Successful treatment with psoralen with ultraviolet A light, interferon‐alfa, and localized radiation , 2018, Pediatric dermatology.

[55]  J. Hlaváč,et al.  DNA interstrand cross-linking agents and their chemotherapeutic potential. , 2012, Current medicinal chemistry.

[56]  M. Whitton,et al.  Interventions for vitiligo. , 2006, The Cochrane database of systematic reviews.

[57]  A. Eastman.  The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. , 1987, Pharmacology & therapeutics.